News
-
The FDA has extended the review period for Optinose’s sNDA seeking approval of Xhance fluticasone propionate nasal spray for the treatment of chronic sinusitis in patients without nasal polyps, Optinose said. Xhance was originally approved… Read more . . .
-
CDMO Recipharm announced that it has hired former Koura Global Business Development Director Simon Gardner as Business Development Specialist for pMDIs to assist customers with the transition to LGWP propellants. Recipharm President, Advanced Delivery Systems, Chris Hirst… Read more . . .
-
Nasus Pharma said that in a second PK study of FMXIN002 intranasal dry powder epinephrine, 91% of subjects who received a 4 mg dose of the nasal formulation reached the clinical threshold for plasma exposure… Read more . . .
-
Kindeva Drug Delivery and Koura Global parent company Orbia Advance Corporation announced that they have partnered to convert a currently marketed metered dose inhaler to use Koura’s HFA 152a (Zephex 152a), a lower global warming potential… Read more . . .
-
Aptar said that the company has won a contract worth up to $6 million from the FDA for a study “designed to provide the FDA with information related to the formulation, manufacture, device design and… Read more . . .
-
Acadia Pharmaceuticals said that it has initiated the Phase 3 COMPASS PWS study of ACP-101 carbetocin nasal spray for the treatment of excessive hunger in people with Prader-Willi syndrome (PWS). Acadia acquired the carbetocin nasal… Read more . . .
-
Scottish device company 1nhaler has raised £2 million for development of a credit-card sized dry powder inhaler in a funding round led by Archangels, the investment firm announced. The 1nhaler device is made out of… Read more . . .
-
Based on results from Part 2 of the Phase 1b/2a trial, BiomX said that it plans to advance its BX004 nebulized phage cocktail for the treatment of chronic P. aeruginosa lung infections in cystic fibrosis… Read more . . .
-
Qnovia (formerly Respira Technologies) has announced results from a Phase 1 trial of its QN-01 inhaled nicotine replacement therapy, which is based on the company’s RespiRx vibrating mesh nebulizer platform. In September 2022, the company… Read more . . .
-
CDMO Hovione has announced a partnership with Industrial Design Consultancy (IDC) for development of two new devices for intranasal delivery of dry powder formulations. According to the announcement, the capsule-based single-use and multidose devices will… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan